How it works
The MES1022 drug-conjugate carries the drug in an inactive state until it binds to the bone. After the targeting moiety binds to bone, the drug is released where it is received by stem cells, stimulating their maturation to osteoblasts (bone-making cells).
How safe is it?
MES1022 avoids systemic exposure and side effects by specifically delivering drugs to the bone.
We have completed GLP toxicity studies in NHPs. It is well tolerated and there were no unexpected toxicity findings.